


Public Reporting of Outcomes for Breast CP3R (Cancer Program Practice Profile Report)

Baylor Scott & White Medical Center - College Station (BSWCS) is committed to providing quality cancer care to our patients. To this end, our cancer program is currently working towards becoming an accredited cancer program through the American College of Surgeons Commission on Cancer, tentatively scheduled for initial survey in 2020. There are roughly 1,500 such accredited cancer programs across the country and Puerto Rico. Accreditation challenges cancer programs to enhance the care they provide by addressing patient-centered needs and measuring the quality of the care they deliver against national standards. Accreditation also ensures a multidisciplinary, team approach to coordinate quality cancer treatment options while offering comprehensive services and equipment. Finally, accreditation demonstrates our cancer program's commitment to provide quality care from prevention through survivorship, with a focus on quality of life.

The Baylor Scott & White Medical Center - College Station Cancer Committee has chosen to publicly report 2017 outcomes for the Breast CP3R (Cancer Program Practice Profile Report) measures. This fulfills one of


Radiation Therapy Administered Following Breast Conserving Surgery (BCSRT)




Radiation therapy is administered within one year (365 days of diagnosis) for women under age 70 receiving breast-conserving surgery for breast cancer. In 2017, 28 of our patients met the criteria for this measure, and 89 percent of those patients received the expected treatment.

Combination Chemotherapy Recommended/Administered for Hormone Receptor Negative Breast Cancer (MAC)

Combination chemotherapy is recommended or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB-III hormone receptor negative breast cancer. In 2017, five of our patients met the criteria for this measure, and 100 percent of those patients received the expected treatment. Our outcomes far surpassed that of other accredited programs in Texas and across the US.




Breast Conserving Surgery (BCS)




Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. In 2017, 68 percent of our patients had breast conservation surgery. BSWCS outcomes are comparable to other COC Community Cancer Programs and All COC accredited cancer programs in the US, but slightly better than accredited programs in Texas. There is no current benchmark for this measure.

Hormone Therapy Recommended/Administered for Hormone Receptor Positive Breast Cancer (HT)

Hormone therapy or third-generation aromatase inhibitor is recommended or administered within one year (365 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB-III hormone receptor positive breast cancer. In 2015, 30 (100%) patients met the criteria for this measure and received the expected treatment. In 2017, 23 patients met the criteria for this measure. Of those, 100% received the expected treatment, exceeding expected benchmark of 90 percent as well as other accredited programs in Tex-



Radiation Therapy Recommended/Administered Following Mastectomy (MASTRT)



Radiation therapy is recommended or administered following any mastectomy within one year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. In 2015, one (100%) patient met the criteria for this measure, and that patient received the expected treatment. Two patients met the criteria for this measure and both patients (100%) received the expected treatment in 2017. BSWCS exceeded the expected benchmark of 90 percent as well as the outcomes reported by other COC accredited programs in Texas and the US.

Needle Biopsy to Establish Diagnosis of Breast Cancer (nBx)

Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer. In 2017, 56 of our patients met the criteria for this measure, and 100% percent of those patients had a needle biopsy to establish a diagnosis of breast cancer. This exceeds the expected benchmark of 80 percent as well as exceeds other accredited cancer programs in Texas and the US.

